Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults

Authors:

Abstract
Hypertension and osteoporotic fractures are age-related disorders whose incidences increase rapidly after the age of 65 years. The conditions are interrelated because people with hypertension have more osteoporotic fractures than people without hypertension.1,2 A meta-analysis3 revealed that many nonrandomized, observational studies suggest that therapy with thiazide-type diuretics improves bone strength and reduces fracture risk. A positive effect on calcium balance and a direct stimulatory effect on osteoblasts have been proposed as the biological basis for this putative beneficial effect.4 β-Blockers may also reduce fracture risk5 (possibly through β2-adrenergic blockade of receptors present on osteoclasts6), although a review article7 found that not all studies confirm this. Less is known regarding the effects of angiotensin-converting enzyme inhibitors (ACEis) and calcium channel blockers (CCBs) on fracture risk despite their ubiquitous use in older adults with hypertension. Studies8,9 have found that ACEis exert a protective effect on bone strength through blockade of local angiotensin production, which stimulates osteoclast activity, and reduction of receptor activator nuclear factor–κβ ligand in osteoblasts, which activates osteoclasts. Several clinical studies suggest lower fracture risk with their use,10,11 although not all studies agree.12-15 Another study16 found that CCBs decrease bone resorption through reduced osteoclast function owing to lower cytosolic calcium. Little information is available regarding their clinical effect on bone health.

This publication has 25 references indexed in Scilit: